Literature DB >> 9328154

Enhanced expression of vascular endothelial growth factor in metastatic melanoma.

P Salven1, P Heikkilä, H Joensuu.   

Abstract

Tumour growth is dependent on angiogenesis. Vascular endothelial growth factor (VEGF) is a secreted endothelial cell-specific cytokine. VEGF is angiogenic in vivo and it also acts as a vascular permeability factor. VEGF is overexpressed in many skin disorders characterized by angiogenesis and increased vascular permeability. We investigated VEGF expression in 22 primary cutaneous melanomas, 33 melanoma metastases and six naevocellular naevi using immunohistochemistry. VEGF accumulated on the vascular endothelia in the normal dermis, suggesting that a constitutive low level of VEGF expression may regulate skin vessel function under normal physiological conditions. No VEGF was detected in the cells of naevocellular naevi or normal dermis. In contrast, 32% of the primary and 91% of the metastatic melanomas contained melanoma cells staining for VEGF. Expression of VEGF was more frequent in metastases than in primary melanomas (P <0.0001). Tumour-infiltrating inflammatory cells expressed VEGF in all melanomas. A high number of VEGF-expressing inflammatory cells was associated with high VEGF expression in melanoma cells (P = 0.003). Our results suggest that VEGF is up-regulated during the course of melanoma progression and dissemination and that tumour-infiltrating cells expressing VEGF may contribute to the progression of melanoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328154      PMCID: PMC2228068          DOI: 10.1038/bjc.1997.486

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

2.  Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors.

Authors:  W Weninger; A Uthman; J Pammer; A Pichler; C Ballaun; I M Lang; A Plettenberg; H C Bankl; M Stürzl; E Tschachler
Journal:  Lab Invest       Date:  1996-11       Impact factor: 5.662

Review 3.  The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.

Authors:  M Denijn; D J Ruiter
Journal:  Melanoma Res       Date:  1993-02       Impact factor: 3.599

4.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; E J Manseau; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

5.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Authors:  D Shweiki; A Itin; D Soffer; E Keshet
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

6.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.

Authors:  D Shweiki; M Neeman; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

7.  Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis.

Authors:  S Banai; D Shweiki; A Pinson; M Chandra; G Lazarovici; E Keshet
Journal:  Cardiovasc Res       Date:  1994-08       Impact factor: 10.787

8.  Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma.

Authors:  M Gutman; R K Singh; S Yoon; K Xie; C D Bucana; I J Fidler
Journal:  Cancer Biother       Date:  1994

9.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.

Authors:  M Detmar; L F Brown; K P Claffey; K T Yeo; O Kocher; R W Jackman; B Berse; H F Dvorak
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

10.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing.

Authors:  L F Brown; K T Yeo; B Berse; T K Yeo; D R Senger; H F Dvorak; L van de Water
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  37 in total

1.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Authors:  Ronald S Go; Sandra J Lee; Donghoon Shin; Steven M Callister; Dean A Jobe; Robert M Conry; Ahmad A Tarhini; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

3.  In vitro antimetastatic effect of Changweiqing through antiinvasion of hypoxic colorectal carcinoma LoVo cells.

Authors:  Jing Li; Zhong-Ze Fan; Jue Sun; Jian-Hua Xu
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

4.  Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis.

Authors:  T G Sheidow; P L Hooper; C Crukley; J Young; J G Heathcote
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

Review 5.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

6.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

Authors:  Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

8.  Angiogenesis and progression in human melanoma.

Authors:  R Ria; A Reale; A Castrovilli; G Mangialardi; F Dammacco; D Ribatti; A Vacca
Journal:  Dermatol Res Pract       Date:  2010-06-06

9.  Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma.

Authors:  Suyun Huang; Lisa Mills; Badar Mian; Carmen Tellez; Marya McCarty; X-D Yang; Jean M Gudas; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Authors:  Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.